OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades [Yahoo! Finance]
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story [Seeking Alpha]
OptimizeRx (NASDAQ:OPRX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
OptimizeRx Continues Expansion of the Company's Point-Of-Care Network [Yahoo! Finance]